Disorders of Pigmentation of the Skin - Hypotheses Underlying Interventions by Multiple Systems of Medicine:Is there a Role for Integrated Medicine?
暂无分享,去创建一个
[1] Y. Lee,et al. Proton pump inhibitors as a possible cause of vitiligo: an in vivo and in vitro study , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[2] T. Ryan,et al. Human pigmentation: A side effect adapted from a primitive organism's survival. Part 2: The melanocyte as mentor of the keratinocye , 2014, Indian dermatology online journal.
[3] T. Ryan,et al. Human pigmentation: A side effect adapted from a primitive organism's survival, acting through cell attachment with an affinity for the keratinocyte and for elastin: Part I , 2014, Indian dermatology online journal.
[4] Q. Sun,et al. Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[5] M. Chatterjee,et al. Pigmentary Disorders: A Comprehensive Compendium , 2014 .
[6] J. Na,et al. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] M. Zheng,et al. Expression of pigment epithelium‐derived factor in human cutaneous appendages , 2013, Clinical and experimental dermatology.
[8] K. Burr,et al. Reprogramming Adult Schwann Cells to Stem Cell-like Cells by Leprosy Bacilli Promotes Dissemination of Infection , 2013, Cell.
[9] O. Shaker,et al. Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[10] L. Kolbe,et al. 4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[11] M. Brilliant,et al. Albinism and disease causing pathogens in Tanzania: are alleles that are associated with OCA2 being maintained by balancing selection? , 2012, Medical hypotheses.
[12] G. Loussouarn,et al. Greying of the human hair: a worldwide survey, revisiting the ‘50’ rule of thumb , 2012, The British journal of dermatology.
[13] Q. Shi,et al. The association of vitamin D receptor gene polymorphisms and serum 25‐hydroxyvitamin D levels with generalized vitiligo , 2012, The British journal of dermatology.
[14] Blazej Zbytek,et al. Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. , 2012, Advances in anatomy, embryology, and cell biology.
[15] Ai-Young Lee. Role of Keratinocytes in the Development of Vitiligo , 2012, Annals of dermatology.
[16] T. Jouary,et al. Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo , 2012, The British journal of dermatology.
[17] H. Y. Kang,et al. Pendulous melanocytes: a characteristic feature of melasma and how it may occur , 2012, The British journal of dermatology.
[18] P. Bahadoran,et al. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations , 2012, The British journal of dermatology.
[19] H. Y. Kang,et al. Defective barrier function in melasma skin , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.
[20] A. Pandya. Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo , 2012 .
[21] W. Westerhof,et al. The effect of H₁ and H₂ receptor antagonists on melanogenesis. , 2012, Indian journal of dermatology, venereology and leprology.
[22] J. Leyden,et al. Natural options for the management of hyperpigmentation , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.
[23] T. Ruzicka,et al. Dead Sea climatotherapy for vitiligo: a retrospective study of 436 patients , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.
[24] D. Kaul,et al. Altered levels of Ets‐1 transcription factor and matrix metalloproteinases in melanocytes from patients with vitiligo , 2011, The British journal of dermatology.
[25] T. Ryan,et al. Collaboration with traditional health practitioners in the provision of skin care for all in Africa , 2011, International journal of dermatology.
[26] T. Ryan,et al. Integrating modern dermatology and Ayurveda in the treatment of vitiligo and lymphedema in India , 2011, International journal of dermatology.
[27] I. Han,et al. Keratinocyte-derived Laminin-332 Promotes Adhesion and Migration in Melanocytes and Melanoma* , 2011, The Journal of Biological Chemistry.
[28] N. Mackman,et al. Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. , 2010, Blood.
[29] Saravu R Narahari,et al. A protocol for systematic reviews of Ayurveda treatments , 2010, International journal of Ayurveda research.
[30] J. Tang,et al. Abnormal DNA methylation in peripheral blood mononuclear cells from patients with vitiligo , 2010, The British journal of dermatology.
[31] P. Elias,et al. Epidermal Permeability Barrier Recovery Is Delayed in Vitiligo-Involved Sites , 2010, Skin Pharmacology and Physiology.
[32] G. Lauzon,et al. Analysis of interleukin‐10 levels in lesions of vitiligo following treatment with topical tacrolimus , 2009, The British journal of dermatology.
[33] H. Kittler,et al. Response of vitiligo to once‐ vs. twice‐daily topical tacrolimus: a controlled prospective, randomized, observer‐blinded trial , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[34] T. Anbar,et al. The hair follicle melanocytes in vitiligo in relation to disease duration , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[35] D. Bani,et al. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. , 2009, Histology and histopathology.
[36] K. Ha,et al. Co‐localization of inducible nitric oxide synthase and phosphorylated Akt in the lesional skins of patients with melasma , 2009, The Journal of dermatology.
[37] G. Schoolnik,et al. Role of Melanin Pigment in Expression of Vibrio cholerae Virulence Factors , 2008, Infection and Immunity.
[38] M J Watts,et al. Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.
[39] Ji-won Park,et al. Molecular Control of Phenoloxidase-induced Melanin Synthesis in an Insect*♦ , 2008, Journal of Biological Chemistry.
[40] M. Namazi. Proton pump inhibitors may trigger vitiligo by rendering melanocytes prone to apoptosis , 2008, The British journal of dermatology.
[41] H. Rokos,et al. From the bench to the bedside: proton pump inhibitors can worsen vitiligo , 2007, The British journal of dermatology.
[42] C‐S. Wu,et al. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo , 2007, The British journal of dermatology.
[43] P. Grimes,et al. The safety of hydroquinone , 2006, Journal of cosmetic dermatology.
[44] J. Reichrath,et al. Cutaneous photosynthesis of vitamin D: an evolutionary highly-conserved endocrine system that protects against environmental hazards including UV-radiation and microbial infections. , 2006, Anticancer research.
[45] O. Turan,et al. Audiological abnormalities in patients with vitiligo , 2006, Clinical and experimental dermatology.
[46] Murad Alam. The Book of Skin , 2006 .
[47] M. Pittelkow,et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo , 2006, Archives of Dermatological Research.
[48] C. Lan,et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo , 2005, The British journal of dermatology.
[49] G. Dogan,et al. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients , 2005, International journal of dermatology.
[50] W. Westerhof,et al. Toxicology and health risks of hydroquinone in skin lightening formulations , 2005 .
[51] T. Hirobe. Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. , 2005, Pigment cell research.
[52] M. Can,et al. The role of oxidants and antioxidants in generalized vitiligo at tissue level , 2004, Journal of the European Academy of Dermatology and Venereology : JEADV.
[53] Graeme Eisenhofer,et al. Tyrosinase: a developmentally specific major determinant of peripheral dopamine , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[54] J. Dangou,et al. Irrational use of skin-bleaching products can delay the diagnosis of leprosy. , 2002, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.
[55] W. Steglich,et al. Pityriacitrin – an ultraviolet-absorbing indole alkaloid from the yeast Malassezia furfur , 2002, Archives of Dermatological Research.
[56] S. Sohn,et al. Melasma: histopathological characteristics in 56 Korean patients , 2002, The British journal of dermatology.
[57] J. Mackintosh. The antimicrobial properties of melanocytes, melanosomes and melanin and the evolution of black skin. , 2001, Journal of theoretical biology.
[58] H. Lim,et al. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. , 2001, Journal of the American Academy of Dermatology.
[59] J. Park,et al. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase‐related protein in vitiligo , 2001, The British journal of dermatology.
[60] G. Vezon,et al. High prevalence of vitiligo in lepromatous leprosy , 2000, International Journal of Dermatology.
[61] A. Pandya,et al. Disorders of hyperpigmentation. , 2000, Dermatologic clinics.
[62] G. Bentham. Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales , 1996, BMJ.
[63] T. F. Cestari,et al. Ultraviolet radiation decreases the granulomatous response to lepromin in humans. , 1995, The Journal of investigative dermatology.
[64] D. Gawkrodger,et al. Neuropeptide and neuronal marker studies in vitiligo , 1994, The British journal of dermatology.
[65] T. Hamilton,et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. , 1994, Archives of dermatology.
[66] T. Hamilton,et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle‐controlled, clinical trial , 1993, The British journal of dermatology.
[67] W. Westerhof,et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. , 1993, The Journal of investigative dermatology.
[68] M. d’Ischia,et al. Mechanism of inhibition of melanogenesis by hydroquinone. , 1991, Biochimica et biophysica acta.
[69] F. Fraschini,et al. T cell subpopulations in vitiligo: a chronobiologic study. , 1990, Journal of the American Academy of Dermatology.
[70] C. Summers,et al. Visual anomalies associated with albinism. , 1990, Ophthalmic paediatrics and genetics.
[71] H. Tagami,et al. Therapeutic success of epidermal grafting in generalized vitiligo is limited by the Koebner phenomenon. , 1990, Journal of the American Academy of Dermatology.
[72] T. Jenkins,et al. Albinism and skin cancer in Southern Africa , 1989, Clinical genetics.
[73] V. Dixit,et al. Production and utilization of extracellular matrix components by human melanocytes. , 1989, Experimental cell research.
[74] R. Falabella. Treatment of localized vitiligo by autologous minigrafting. , 1988, Archives of dermatology.
[75] H. Hönigsmann,et al. Treatment of vitiligo with khellin and ultraviolet A. , 1988, Journal of the American Academy of Dermatology.
[76] A. Sober,et al. Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin. , 1988, Dermatologic clinics.
[77] A. Rebora,et al. Racial differences in experimental skin infection with Candida albicans. , 1988, Acta dermato-venereologica.
[78] M. Yasutomi,et al. Migration of epidermal melanophores to the dermis through the basement membrane during metamorphosis in the frog, Rana japonica. , 1987, Pigment cell research.
[79] A. P. Kelly,et al. Natural cell-mediated cytotoxicity in vitiligo. , 1987, Journal of the American Academy of Dermatology.
[80] R. Halaban,et al. Transplantation of human melanocytes. , 1987, The Journal of investigative dermatology.
[81] D. F. Roberts,et al. Differentiation of heterozygotes in recessive albinism. , 1986, Journal of medical genetics.
[82] T. Jenkins,et al. Prevalence of albinism in the South African negro. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[83] M. Mihm,et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. , 1981, Journal of the American Academy of Dermatology.
[84] A. Peserico,et al. Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin-producing cells. , 1979, Archives of dermatology.
[85] M. Porro,et al. The monoene fatty acids of human surface lipids and their relation to skin melanogenesis , 1977 .
[86] J. Parrish,et al. Monobenzylether of hydroquinone , 1977, The British journal of dermatology.
[87] J. Parrish,et al. Photochemotherapy of vitiligo. Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. , 1976, Archives of dermatology.
[88] R. N. Macsween,et al. Serum anti‐tumour antibodies and auto‐antibodies in vitiligo , 1975, The British journal of dermatology.
[89] T. Fitzpatrick,et al. Mechanism of depigmentation by hydroquinone. , 1974, The Journal of investigative dermatology.
[90] E. Kandil. Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol--a double-blind trial. , 1974, The British journal of dermatology.
[91] H. Cameron,et al. Nephrotic Syndrome in Adult Africans in Nairobi , 1972, British medical journal.
[92] S. Bleehen,et al. TREATMENT OF VITILIGO WITH ORAL 4,5′,8‐TRIMETHYLPSORALEN (TRISORALEN) , 1972, The British journal of dermatology.
[93] A. Lerner. On the etiology of vitiligo and gray hair. , 1971, The American journal of medicine.
[94] G. Kahn. Depigmentation Caused by Phenolic Detergent Germicides , 1971 .
[95] T. Ryan,et al. FIBRINOLYTIC ACTIVITY IN LESIONS PRODUCED BY MONOCHROMATOR ULTRAVIOLET IRRADIATION IN VARIOUS PHOTODERMATOSES , 1970, The British journal of dermatology.
[96] R. Dawber. Clinical associations of vitiligo , 1970, Postgraduate medical journal.
[97] David J. Wolf,et al. Poikiloderma vasculare atrophicans , 1970, Cancer.
[98] T. Fitzpatrick,et al. Depigmentation of skin with 4-isopropylcatechol, mercaptoamines, and other compounds. , 1968, The Journal of investigative dermatology.
[99] M. Corcos. The clinical dynamics of pigment loss (a study of 71 lesions in eastern Nigerians). , 1966, Leprosy review.
[100] M. Birbeck,et al. An Electron Microscope Study of Basal Melanocytes and High-Level Clear Cells (Langerhans Cells) in Vitiligo * , 1961 .
[101] L. Schwartz,et al. Occupational Leukoderma. Preliminary Report. , 1939 .